期刊文献+

PPARγ和RXRα配体联用对白血病细胞生长作用机制的研究 被引量:1

Up-expression of peroxisome proliferator-activated receptor-γ and of retinoid X receptor-α enhances the inhibitory effect on leukemia cells
原文传递
导出
摘要 目的研究过氧化物酶体增生物活化受体(PPARγ)和维甲类X受体(RXRα)在人类白血病细胞(HL-60、K562、U937)中的表达及其对配体作用的反应。方法采用MTT法检测细胞生长;半定量RT-PCR法检测PPARγ和RXRα mRNA的表达。结果PPARγ和RXRα在HL-60细胞中有较强表达,在K562、U937细胞中表达较弱。PPARγ的配体土槿乙酸(PLAB)能显著抑制3株细胞的生长,PLAB与RXRα的配体9-顺式维甲酸(9-cisRA)联合作用时,与PLAB单独作用比较,对受体高表达的HL-60细胞抑制作用增强较明显(P〈0.05),但对K562、U937的作用增强不明显(P〉0.05)。PLAB和9-cisRA分别上调HL-60细胞PPARγ和RXRα的表达,且联合作用组显著高于单独作用组(P〈0.05)。结论在HL-60、K562、U937细胞中,HL-60细胞PPARγ和RXRα表达最强,这对配体发挥作用可能是必需的,配体发挥的抑制细胞生长的效应可能与其介导的信号途径有关。 Objective To investigate the relationship between the expression of peroxisome proliferators-activated recepter-γ (PPARγ) and retinoid X receptor-α (RXRα) and the inhibitory effect of PLAB, ligand of PPARγ and 9-cisRA, ligand of RXRα on growth of human leukemia cell lines (HL-60, K562 and U937) in vitro. Methods The antiproliferative effect was evaluated by MTT assay. The mRNA expression of PPARγ and RXRα was semi-quantified by RT-PCR. Results PPARγ and RXRα mRNA was both expressed in HL-60, K562 and U937 cells, and the expression in HL-60 was significantly higher than that in K562 and U937. The significant inhibitory effect on the growth of HL-60 cells was observed in K562 and U937 cells. The combination group showed more inhibitory effect in HL-60 cells than PLAB alone(P 〈0.05). PLAB significantly up-regulates the expression of PPARγ in HL-60 cells, the expression of PPARγ and RXRα were higher in combination group than PLAB alone (P 〈0.05). Conclusion The expression of PPARγ and RXRα in HL-60, K562 and U937 cell lines predicts their response to PLAB and 9-cisRA treatment, and the inhibitory effect is different in these three kinds of cell lines, which may be related to their ligands - mediated signal pathway.
出处 《白血病.淋巴瘤》 CAS 2009年第3期131-133,共3页 Journal of Leukemia & Lymphoma
基金 基金项目:国家自然科学基金(30171108)
关键词 白血病 PPARΓ RXRα Leukemia PPARγ RXRα
  • 相关文献

参考文献9

  • 1Yamazaki K, Shimizu M, Okuno M. Synergistic effects of RXR α and PPARγ ligands to inhibit growth in human colon cancer cells-phosphorylated RXR α is a critical target for colon cancer management. Gut, 2007, 56: 1557-1563.
  • 2Dai Y, Qiao L, Chan KW. Loss of XIAP sensitizes rosiglitazone-induced growth inhibition of colon cancer in vivo. Cancer, 2008, 122: 2858-2863.
  • 3Klopper JP, Hays WR, MargaretA VS, et al. Retinoid X receptor-α and peroxisome proliferators-activated receptor- γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther, 2004, 3:1011-1020.
  • 4Jardat MS, Noonan D J, Wu B, et al. Pseudolaric acid analogs as a new class of peroxisome proliferator - activated receptor agonists. Planta Med, 2002, 68:667-6711.
  • 5Segawa Y, Yoshimura R, Westin S, et al. Expression of peroxisome proliferators-activated receptor (PPAR) in human prostate cancer. Prostate, 2002, 51:108-116.
  • 6Klopper JP, Hays WR, Margareta VS, et al. Retinoid X receptor-γ and peroxisome proliferators-activated receptor- γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther, 2004, 3:1011-1020.
  • 7孟爱国,徐瑞成,呼文亮.吡格列酮对胃癌细胞生长的影响及其机制[J].肿瘤防治研究,2006,33(5):334-336. 被引量:5
  • 8徐瑞成,孟爱国,呼文亮.PPARγ和RXRα的表达上调增强了对肿瘤细胞生长的抑制作用[J].基础医学与临床,2007,27(3):254-258. 被引量:7
  • 9Brockman J, Gupta R. Activation of PPAR γ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology, 1998, 115: 1049-1055.

二级参考文献14

  • 1夏学巍,苏长保.PPARγ受体激动剂抗肿瘤作用机制研究进展[J].基础医学与临床,2005,25(12):1109-1113. 被引量:11
  • 2马秀梅,左连富,刘江惠,郭建文,刘颖.人胃癌组织中PPARγ的表达及其配体对胃癌细胞生长的影响[J].基础医学与临床,2006,26(3):294-301. 被引量:8
  • 3Michalik L,Desvergne B,Wahli W.Peroxisome proliferatorsactivated receptors and cancers complex stories[J].Nat Rev Cancer,2004,4 (1):61-70.
  • 4Gramura C,Landreth GE,Heneka MT.Antineoplastic effects of peroxisome proliferator-activated receoptor gamma agonists[J].Lancet Oncol,2004,5(7):419-429.
  • 5Nobuhiko T,Toshikatsu O,Wataru M,et al.Activation of peroxisome proliferators-activated receptor γ inhibition cell growth and induce apoptosis in human gastric cancer cells[J].FEBS Letters,1999,455 (1),135-139.
  • 6king KI,Cidlowski JA.Cell cycle regulation and apoptosis[J].Annu Rev Physiol,1998,60 (1):601-617.
  • 7Zander T,KrausJA,Gramres C,et al.Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPAR gamma[J].J Neurochem,2002,81 (5):1052-1060.
  • 8Kim EJ,Parkk S,Chung SY,et al.Peroxisome proliferators-activated receptor gammga activator 15-deoxy-delta12 14-prostagl and in J2 inhibits neuroblastama cell growth through induction of apoptosis association with extracellular signal-regulated kinase signal pathway[J].J Phamracol Exp Ther,2003,307(5):505-517.
  • 9Michalik L, Desvergne B,Wahli W. Peroxisome proliferators-activated receptors and cancers complex stories [ J ].Nat Rev Cancer,2004,4 : 61 - 70.
  • 10Segawa Y,Yoshimura R, Hase T,et al. Expression of peroxisome proliferators- activated receptor (PPAR) in human prostate cancer[J]. Prostate,2002,51 : 108 - 116.

共引文献7

同被引文献13

  • 1Fernandez CA, Puig-Domingo M, Lomenna F, et ai. Effectiveness ofretinoic acid treatment for redifferentiation of thyroid cancer in relationto recovery of radioiodine uptake. J Endocrinol Invest, 2009,32: 228-233.
  • 2Patel A, Jhiang S, Dogra S, et al. Differentiated thyroid carcinomathat express sodium-iodide symporter have a lower risk of recurrencefor children and adolescents. Pediatr Res, 2002, 52: 737-744.
  • 3Doh n n 0, Baloch Z, B 6 nr 6 vi Z, et al. Rapid communication :predominant intracellular overexpression of the Na+/I- symporter (NIS)in a large sampling of thyroid cancer case. J Clin Endocrinol Melab,2001,86: 2697-2700.
  • 4Riesco-Eizaquirre G, Guti 6 rrez-Martiez P, Garcia-Cabezas MA, et al.The oncogene BRAF V600E is assciatted with a high risk ofrecurrence and differentiated papillary thyoid carcinoma due to theimpairmeat of Na+/I- targeting to the membrane. Endocr RelatCancer, 2006, 13: 257-269.
  • 5Ricarte-Filho JC, Ryder M,Chitale DA, et al. Mutational profile ofadvanced primary and metastatic radioactive iodine-refractory thyroidcancers reveals distinct pathogenetic roles for BRAF, PIK3CA, andAKT1. Cancer Res, 2009, 69: 4885-4893.
  • 6Gruning T, Tiepolts C, Zophel K, et al. Retinoic acid forredifferentiation of thyroid oancer-dose it hold its promise. Eur JEndocrinol, 2003, 148: 395-402.
  • 7Kang HJ, Youn YK, Hong MK, et al. Antiproliferation andredifferentiation in thyroid cancer cell lines by polyphenolphytoohemicals. J Korean Med Sci, 2011,26: 893-899.
  • 8Liu X,Chan SY, Ho PC. Comparison of the in vitro and in vivoeffects of retinoids either alone or in combination with cisplatin and 5-fluorouracil on tumor development and metastasis of melanoma. JCancer Chemother Pharmacol, 2008, 63: 167-174.
  • 9Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids inredifferentiation therapy of advanced thyroid cancer: final results of apilot study. Eur J Nucl Med Mol Imaging, 2002,29: 775-782.
  • 10Grunwald F, Menzel C, Bender H, et al. Redifferentiation therapyinduced radioiodine uptake in thyroid cancer. J Nucl Med, 1998, 39:1903-1906.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部